Aristotle Capital Boston, LLC, an investment advisor, released its first-quarter 2026 investor letter for “Small Cap Equity Fund”. A copy of the letter is available to download here. U.S. small-cap equities delivered strong performance in the first quarter amid macroeconomic and geopolitical volatility, outpacing large-cap stocks. Improving earnings, attractive relative valuations, and a focus on domestic sectors supported the small caps in the quarter. In this backdrop, the Aristotle Small Cap Equity Fund (Class I-2) delivered a total return of 1.50% in the quarter, outperforming the Russell 2000 Index’s 0.89% return. The performance was supported by security selection in the information technology and financials sectors, along with underweight allocations to healthcare and industrials. The fund remains optimistic about the long-term outlook for U.S. small-cap equities. Please review the Strategy’s top five holdings to gain insights into their key selections for 2026.
In its first-quarter 2026 investor letter, Aristotle Small Cap Equity Fund highlighted stocks like Haemonetics Corporation (NYSE:HAE). Haemonetics Corporation (NYSE:HAE) is an innovative medical technology company that provides solutions for improving patient care. On April 20, 2026, Haemonetics Corporation (NYSE:HAE) closed at $59.56 per share. One-month return of Haemonetics Corporation (NYSE:HAE) was 0.10%, and its shares lost 9.98% over the past 52 weeks. Haemonetics Corporation (NYSE:HAE) has a market capitalization of $2.71 billion.
Aristotle Small Cap Equity Fund stated the following regarding Haemonetics Corporation (NYSE:HAE) in its Q1 2026 investor letter:
“Haemonetics Corporation (NYSE:HAE) is a global provider of hematology and blood management products and solutions. The company’s shares weakened following its earnings release, despite results beating analyst expectations. Investor reaction was driven by a reported year-over-year revenue decline tied to planned portfolio transitions which overshadowed solid underlying demand and margin expansion. We believe that the company’s strong competitive position within the plasmapheresis market along with increased investment in research and development should create value for shareholders over a multi-year period.”
Haemonetics Corporation (NYSE:HAE) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 33 hedge fund portfolios held Haemonetics Corporation (NYSE:HAE) at the end of the fourth quarter, compared to 36 in the previous quarter. Haemonetics Corporation (NYSE:HAE) reported revenue of $346 million in the fourth quarter of 2026, an increase of 5% on a reported and 9% on an organic basis. While we acknowledge the risk and potential of Haemonetics Corporation (NYSE:HAE) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Haemonetics Corporation (NYSE:HAE) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Haemonetics Corporation (NYSE:HAE) and shared Riverwater Sustainable Value Strategy’s views on the company. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
